Vanguard Group Inc Virpax Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.24 - $0.82 $275 - $942	1,149 Added 1.76%	66,294 $21,000
Q1 2023 May 15, 2023	SELL	$0.67 - $1.15 $75,435 - $129,479	-112,591 Reduced 63.35%	65,145 $50,000
Q4 2022 Feb 10, 2023	SELL	$0.62 - $12.0 $119,751 - $2.32 Million	-193,148 Reduced 52.08%	177,736 $110,000
Q3 2022 Nov 14, 2022	BUY	$1.15 - $11.9 $33,243 - $343,993	28,907 Added 8.45%	370,884 $441,000
Q1 2022 May 13, 2022	BUY	$1.86 - $3.61 $27,289 - $52,965	14,672 Added 4.48%	341,977 $759,000
Q4 2021 Feb 14, 2022	BUY	$3.19 - $4.89 $154,029 - $236,113	48,285 Added 17.31%	327,305 $1.12 Million
Q3 2021 Nov 12, 2021	BUY	$4.14 - $22.9 $1.16 Million - $6.39 Million	279,020 New	279,020 $1.34 Million

Ticker VRPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,714,600
Market Cap $7.15M
Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical no...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.